First-half earnings per share fell 2.8% year-on-year while revenue climbed 17% to ¥663,300M.
Chugai Pharmaceutical reported first-half earnings per share of ¥140.82, down from ¥144.84 a year earlier. Revenue reached ¥663,300M, driven by product sales of ¥566,500M and other revenue of ¥96,800M.
Operating profit declined to ¥319,600M from ¥329,100M in the prior period. Costs included ¥197,000M in cost of sales, ¥89,600M in R&D expenses, and ¥57,900M in SG&A expenses.
The release showed a net financial income of ¥9,600M and other operating income of ¥900M.